Fosamax and other bisphosphonates: Did they cause your atypical fracture?
The Los Angeles Times reported yesterday on the latest links between bisphosphonates (such as Fosamax) and atypical bone fractures.
This is yet another example of dangerous risks appearing long after the FDA approved a prescription. Do you think pharmaceutical companies need to be more accountable when studies come to these types of conclusions?
Tell us what you think.
